USAN Council's statement on the use of USAN as domain names is that a name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names website shall be the effective equivalent of an intellectual property right for the relevant entities.
Visit United States Adopted Names FAQ to learn more.
Comments or protests should be addressed to Stephanie Shubat, USAN program director, American Medical Association, 330 North Wabash Ave., Suite 39300, Chicago, Illinois 60611, or via email: [email protected].
In order to ensure your "under consideration" USAN domain name is available, you should consider purchasing the .com, .net and .org domain names of the USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.
The following names for the drugs described are "under consideration" by the USAN Council:
July 2026
Abdakibart: Treatment of hidradenitis suppurativa
Abelacimab: Treatment of thromboembolic diseases
Alcudacigib: Antineoplastic
Alcudacigib fumarate: Antineoplastic
Anzutresgene autoleucel: Treatment of solid tumors
Beperminogene perplasmid: Treatment of chronic limb-threatening ischemia (CLTI)
Dalnacogene ponparvovec: Treatment of hemophilia B
Ebselen: Treatment of hearing loss and tinnitus in patients with Meniere’s disease
Elsunersen: Treatment of developmental epileptic encephalopathy (DEE)
Elsunersen sodium: Treatment of developmental epileptic encephalopathy (DEE)
Ensavatatug: Treatment of advanced or metastatic solid tumors
Invobenitug: Treatment of cardiogenic shock (CS)
Izicopan: Treatment of treatment of urticaria (CSU) and hidradenitis
Neridronic acid: Treatment of complex regional pain syndrome (CRPS)
Neriodronate sodium: Treatment of complex regional pain syndrome (CRPS)
Olsutamig: Treatment of prostate cancer
Selcodebart: Treatment of anemia
Tacabrutideg: Treatment of B-cell malignancies
Tegoprazan: Treatment and maintaining healing for erosive esophagitis and treatment of non-erosive gastroesophageal reflux disease
Vemzatatug: Treatment of multiple myeloma
Vemzatatug vedotin: Treatment of multiple myeloma
Voderdeucitinib: Treatment of plaque psoriasis
June 2026
Acmopatide: Treatment of type 1 diabetes and obesity
Enicepatide: Treatment of patients with locally advanced or metastatic solid tumors
Ercanetide: Treatment of neurodevelopment disorders including Angelman syndrome, Phelan-McDermid syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome
Ibramvibart: Prevention and treatment of infections caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV-2)
Laromestrocel: Treatment of Alzheimer's disease, aging frailty, hypoplastic left heart syndrome, and pediatric dilated cardiomyopathy
Lead Pb 212 oxoreotide atexetan citrate: Treatment of somatostatin receptor expressing neuroendocrine tumors (NETs)
Libenucgene parvec: Treatment of ornithine transcarbamylase (OTC) deficiency
Nizubaglustat: Treatment of Niemann-Pick C GM1 and GM2 gangliosidoses Gaucher type 3
Onzemipgene parvec: Treatment of Age-related Macular Degeneration (AMD)
Pumitamig: Treatment of cancer
Raplemomeran: Treatment of HPV16+ cancer
Relutrigine: Treatment of seizures associated with developmental and epileptic encephalopathies (DEE)
Rezotcagene parvec: Treatment of ornithine transcarbamylase (OTC) deficiency
Ristoglogene autogetemcel: Treatment of sickle cell disease (SCD)
Sitmutolimod: Treatment of relapsed or refractory advanced solid tumors
Surovatamig: Treatment of hematologic malignancies and autoimmune diseases
Tenumomeran: Treatment of HPV16+ cancer
Turletricin: Antifungal agent
Zavabresib: Antineoplastic
Zidebactam: Antibacterial; treatment of urinary tract infections
Zovegalisib: Treatment of advanced solid tumors
May 2026
Amrecibart: Prevention and treatment of thromboembolic diseases
Atebimetinib: Antineoplastic, treatment of solid tumors
Bocunebart: Treatment of headache, migraine and other conditions that may benefit from the neutralization of PACAP
Cenvacibart: Prevention and treatment of thromboembolic diseases
Darlifarnib: Treatment of advanced solid tumors
Elisrasib: Antineoplastic, treatment of advanced solid tumors
Elecoglipron: Treatment of type 2 diabetes and weight management
Giredestrant tartrate: Treatment of cancer
Ifezuntirgene inilparvovec: Treatment of Huntington’s Disease
Mazorelvimab: Treatment for rabies virus (RABV) infections
Mivocabtagene autoleucel: Treatment of Stiff Person Syndrome (SPS)
Mosliciguat: Treatment of pulmonary hypertension
Nexiguran: Treatment of transthyretin amyloidosis (ATTR)
Nuzefatide: Treatment of patients with EphA2 expressing tumors
Nuzefatide pevedotin: Treatment of patients with EphA2 expressing tumors
Palacaparib: Treatment of advanced solid tumors
Pivodisgene parvec: Treatment of Duchenne muscular dystrophy (DMD)
Resecabtagene autoleucel: Treatment of systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM, or myositis), systemic sclerosis (SSc), and other B cell driven autoimmune diseases
Sasineprocel: Treatment of Parkinson’s disease
Soclenicant: Treatment of anxiety-, trauma-, and stressor-related disorders
Velaprumig: Treatment of thyroid eye disease (TED, Graves’ ophthalmopathy)
Zamerovimab: Treatment against rabies virus infections
Zeprumetostat: Antineoplastic
Ziclumeran: Treatment of transthyretin amyloidosis (ATTR)
